PowerVision, a medical device company developing the world's first fluid-based accommodating intraocular lens, announced that it completed its $30 million Series D financing. Aisling Capital, Correlation Venture Partners and existing investor Venrock contributed $10 million, adding to the $20 million raised earlier this year. The capital will be used to complete patient enrollment in the ongoing CE Mark study for the company's FluidVision lens. The fluid-based lens restores vision to those affected by presbyopia and/or cataracts. Inserted in the eye, it thins or thickens by moving fluids through internal channels using natural forces of the eye, aiding the eye in focusing. PowerVision last raised funds in January of 2012 in a round of over $37 million valuing the company at almost $79 million.